Zymeworks Inc (ZYME)
NASDAQ:ZYME
Want to see ZYME full AI Analyst Report?
ZYME Stock Chart & Stats
$27.80
-$0.11(-0.77%)
At close: 4:00 PM EST
$27.80
-$0.11(-0.77%)
Day’s Range― - ―
52-Week Range$10.86 - $28.88
Previous CloseN/A
Volume35.38K
Average Volume (3M)641.83K
Market Cap
$2.10B
Enterprise Value$2.02B
Total Cash (Recent Filing)$228.80M
Total Debt (Recent Filing)$18.27M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
May 07, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding73,749,600
10 Day Avg. Volume568,261
30 Day Avg. Volume641,831
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.39
Price to Sales (P/S)18.72
P/FCF Ratio-57.45
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue19.02
Enterprise Value/Gross Profit19.33
Enterprise Value/Ebitda-22.57
Forecast
1Y Price Target
$39.75Price Target Upside42.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.13
Revenue Forecast (FY)$294.64M
Bulls Say, Bears Say
Bulls Say
Capital Flexibility From Royalty FinancingRoyalty‑backed financing strengthens liquidity while preserving core royalty streams, enabling potential share repurchases or targeted acquisitions to increase strategic optionality.
Partnerships And Royalty RevenueEstablished collaboration agreements and tiered royalty arrangements create clear pathways for milestone and royalty payments that can generate recurring revenue as partner programs advance.
Regulatory ProgressBreakthrough and Fast Track designations for zanidatamab and ZW191 add regulatory de‑risking and could materially expand addressable markets if approvals are secured.
Bears Say
Competitive Pressures In FRa ADC FieldA competing FRa‑targeting therapy with prior Breakthrough recognition heightens competitive pressure and could limit market share and pricing power for similar ADC candidates.
Funding And Dilution RiskPersistent operating losses, high cash burn and reliance on milestone or royalty receipts increase the likelihood of dilutive financing or program delays if expected payments do not materialize.
Safety And Tolerability RisksReported serious treatment‑related adverse events and chemotherapy discontinuations in partner programs raise safety concerns that could restrict clinical adoption and delay development timelines.
Zymeworks News
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $10.86 and its highest was $28.88 in the past 12 months.
What is Zymeworks Inc’s market cap?
Zymeworks Inc’s market cap is $2.10B.
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is May 07, 2026 which is in 13 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Mar 02, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.461 by -$0.089.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -0.3.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 73,749,600 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.461. Following the earnings report the stock price went up 0.086%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Currently, no hedge funds are holding shares in ZYME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.75 (42.99% Upside)
$39.75 (42.99% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 505.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.6%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.11%
12-Months-Change
Fundamentals
Return on Equity
-26.00%
Trailing 12-Months
Asset Growth
-25.17%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME Company Deck
ZYME Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive clinical and commercial momentum centered on zanidatumab — a Phase III survival result (median PFS >1 year, median OS >2 years), regulatory progress, material near- and longer-term milestone and royalty economics, a $250M nondilutive financing structured to preserve long-term upside, and meaningful revenue growth (~39% y/y) with an improved net loss (≈34% reduction). Management reiterated cost discipline (targeting ~20% lower adjusted operating expense in 2026) and pipeline progress (ZW251 enrolling, INDs on track for 2026). Key risks include reliance on contingent milestone payments for runway, a ~16.5% decline in cash year-over-year, some near-term encumbrance of 30% of zanidatumab royalties to service the note, and remaining clinical/regulatory uncertainties (e.g., next OS interim and multi-year timelines for breast cancer readouts). On balance, the positive clinical validation, revenue/milestone upside, and strategically structured nondilutive financing materially outweigh the risks presented.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$39.75
▲(42.99% Upside)
Technical Analysis
Arcus Biosciences
―
Replimune Group
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
Currently, No data available
---